Two forms of human tryptophanyl-tRNA synthetase (TrpRS) are produced in vivo through alternative mRNA splicing. The two forms, full-length TrpRS and mini TrpRS, are catalytically active, but are distinguished by the striking anti-proliferative and antiangiogenic activity speci®c to mini TrpRS. Here we describe two new splice variants of human TrpRS mRNA. Their production was strongly regulated by g-interferon (IFN-g), an anti-proliferative cytokine known to stimulate the expression of other antiangiogenic factors. A new IFN-g-sensitive promoter was demonstrated to drive production of these splice variants. In human endothelial cells, both the newly discovered and a previously reported promoter were shown to respond speci®cally to IFN-g and not to other cytokines such as tumor necrosis factor-a, transforming growth factor-b, interleukin-4 or erythropoietin. In addition, both promoters were stimulated by the`downstream' interferon regulatory factor 1 that, in turn, is known to be regulated by the`upstream' signal transducer and activator of transcription 1a subunit. Thus, the tandem promoters provide a dual system to regulate expression and alternative splicing of human TrpRS in vivo.
INTRODUCTION
Aminoacyl-tRNA synthetases are essential enzymes that covalently link amino acids to their cognate tRNAs (1, 2) . The 20 enzymes are divided into two groups of 10 each (3±6). Class I enzymes share a common active site architecture which includes a Rossmann fold nucleotide-binding domain (7) . The active sites of class II enzymes are made up of a seven-stranded antiparallel b-sheet¯anked by a-helices (6, 8) . During their long evolution, many tRNA synthetases acquired extra domains in addition to the core active site structures. Initially, these extra domains added speci®city to the aminoacylation reactions. Later additions and sequence adaptations, like those seen in mammalian synthetases, contribute to the additional cellular functions seen in several enzymes (9, 10) . Typically the added functions developed alongside the activity of tRNA synthetases in translation.
A striking example of functional expansion is human tyrosyl-tRNA synthetase (TyrRS), which is processed by the extracellular protease leukocyte elastase to release two fragments, one with IL-8-like cytokine and pro-angiogenic activity (mini TyrRS) and the other with EMAP II-like cytokine activity (C-domain) (11, 12) . Signi®cantly, the unprocessed full-length enzyme lacks the cytokine activities. The closely related human enzyme tryptophanyl-tRNA synthetase (TrpRS) developed anti-angiogenic activity in the naturally occurring variant called mini TrpRS but not in the full-length, native protein (13, 14) . Several recent reports revealed that other mammalian synthetases have unique cellular activities beyond translation. For example, glutaminyl-tRNA synthetase inhibits apoptosis (15) and histidyl-tRNA synthetase stimulates in¯ammation signal transduction pathways (16) . While these particular specializations and functional expansions show the remarkably versatile activities associated with particular tRNA synthetases, others have evolved secondary functions related to RNA processing such as human rRNA maturation, which requires methionyltRNA synthetase (17) , mitochondrial tyrosyl-tRNA synthetase-dependent splicing of group I introns in the fungi Neurospora and Podospora (18, 19) and splicing of the fourth intron (bI4) of the Saccharomyces cerevisiae cob gene by mitochondrial leucyl-tRNA synthetase (20) .
Among tRNA synthetases with expanded functions, human TrpRS was one of the ®rst studied. Early work established that TrpRS underwent limited proteolysis and was secreted from bovine pancreas (21, 22) . In separate studies, a truncated variant of human TrpRS (mini TrpRS) was demonstrated to be produced by alternative splicing in vivo (23, 24) . This variant, along with the full-length enzyme, was strongly up-regulated by IFN-g (23, 25) (Fig. 1A) . The rationale and biological signi®cance of IFN-g regulation and truncated TrpRS forms were unknown.
Recent work showed that three related variants of human TrpRS, mini TrpRS, T1-TrpRS and T2-TrpRS, have potent anti-angiogenic activity (13, 14) . Thus, mini TrpRS blocked vascular endothelial growth factor (VEGF)-induced proliferation and migration of human umbilical vein endothelial cells (HUVECs) (13) and inhibited angiogenesis in chick chorioallantoic membranes, in a mouse matrigel model and in a mouse model of post-natal blood vessel development in the retina (13, 14) . Retinal vessel development is well correlated with VEGF expression and direct suppression of VEGF signaling effectively inhibited neovascularization (26, 27) . While the mechanistic details of mini TrpRS inhibition are not yet known, VEGF-mediated angiogenesis was inhibited by mini TrpRS. In the retina, T2-TrpRS potently inhibited blood vessel development and was localized to pre-existing blood vessels (14) . These results collectively suggest that T2-TrpRS acts directly on existing blood vessels to inhibit further development. The discovery that these fragments of TrpRS have anti-angiogenic activity provided a biological rationale for their production.
IFN-g is a pleiotropic cytokine that induces an antiproliferative cellular state and regulates expression of over 200 genes, some of which are involved in host defense or in¯ammation (28) . Other IFN-g-regulated genes, like interferon-inducible protein-10 (IP-10), monokine induced by g-interferon (MIG) and mini TrpRS, are anti-angiogenic factors (29, 30) . Although some lymphoid cell lines do not exhibit TrpRS regulation by IFN-g, expression of TrpRS is speci®cally up-regulated by IFN-g in epithelial cells and ®broblasts (31±33). Given a biological rationale for production of fragments of TrpRS and the role of IFN-g in regulating expression of anti-angiogenic factors, we were particularly interested in examining the regulation of TrpRS and mini TrpRS in endothelial cells. The idea was to provide a framework for understanding how the remarkable activities of this human tRNA synthetase are generated and controlled. This framework, in turn, gave us the basis to establish a working model explaining how multiple factors control expression of this tRNA synthetase.
MATERIALS AND METHODS

Cell culture
HUVECs were obtained from Clonetics (Walkersville, MD) and maintained in EGM â -2 BulletKit â medium (Clonetics) in an atmosphere of 5% CO 2 in air at 37°C according to the instructions of the supplier. HeLa cells were obtained from Clontech (Palo Alto, CA) and maintained in Dulbecco's modi®ed Eagle's medium supplemented with 10% inactivated fetal bovine serum and antibiotics. HUVECs were treated with IFN-g (Roche, Mannheim, Germany) at 50±500 U/ml, tumor necrosis factor-a (TNF-a) (Roche) at 500±1000 U/ml, transforming growth factor-b (TGF-b) (Roche) at 0.1±2 nM, interleukin-4 (IL-4) (R&D Systems, Minneapolis, MN) at 10± 100 U/ml, erythropoietin (Epo) (Sigma, Saint Louis, MI) at 4 U/ml or human interferon-a (IFN-a) (Sigma) at 500 U/ml for 0±48 h incubation.
Reverse transcription±PCR (RT±PCR)
After treatment with IFN-g or other cytokines, HUVECs (1 Q 10 6 cells) were harvested at the times indicated, washed twice with ice-cold phosphate-buffered saline (PBS) and collected by centrifugation. Total RNA was isolated from HUVECs using the RNeasy Midi kit (Qiagen, Chatsworth, CA) according to the manufacturer's instructions. Total RNA (1 mg) in 15 ml was converted to complementary DNA (cDNA) using M-MLV reverse transcriptase and an anchored oligo(dT) primer set following the manufacturer's protocol (Qiagen). A 2 ml aliquot of the resulting cDNA was used as template for PCR ampli®cation with speci®c primers: human TrpRS, pJL50 (forward, exon ±Ia, 5¢-GAGCGCTGACTGGCC-CGGCTGGG-3¢) and pJL51 (reverse, exon III, 5¢-ATG-AGCTTATCGTAGTCTATGCC-3¢) or pKLEA (forward, exon Ia, 5¢-AGCTCAACTGCCCAGCGTGACC-3¢) and pKLEB (reverse, exon III, 5¢-CAGTCAGCCTTGTAATCC-TCCCCC-3¢); human glyceraldehyde 3-phosphate dehydrogenase (GAPDH), pKLEC (forward, 5¢-GGTCGGAGT-CAACGGATTT-3¢) and pKLED (reverse, 5¢-CCAGCA-TCGCCCCACTTGA-3¢). The ampli®cations were performed by initial denaturation (94°C for 1 min), 30 cycles of denaturation, annealing and extension (94°C for 1 min, 60°C for 45 s and 72°C for 45 s), and ®nal extension (72°C for 10 min). The transcript of GAPDH was also ampli®ed by RT± PCR from the same cDNA template and was used as an internal control. The resulting PCR products were resolved by 1.2% agarose gel electrophoresis and cloned into a pCR â 4-TOPO vector (Invitrogen, Carlsbad, CA). The identity of each DNA band was con®rmed by DNA sequencing.
Northern blot analysis
Total RNA (10 mg) was separated by electrophoresis in a 1% agarose/2.2 M formaldehyde gel, capillary transferred to a Zeta-Probe GT Genomic positively charged nylon membrane (Bio-Rad) with 10Q SSC. The membrane was UV crosslinked using a HL-2000 HybriLinker (Upvon, Upland, CA). Oligonucleotide probes speci®c for the different TrpRS transcript isoforms were radioactively labeled with [a-32 P]- (23, 36) . The position of exon ±Ia is ±1458 to ±912. Two promoters are indicated as P1 and P2. GAS, g-activated sequence; ISRE, interferon-stimulated response element. dCTP (3000 Ci/mmol; Amersham Pharmarcia Biotech Inc., Piscataway, NJ) by random priming (Promega, Madison, WI) and used as probes to hybridize with the total RNA samples. The blots were hybridized at 55±65°C for 20 h in hybridization solution as described (34) . Detection was performed with a PhosphorImager screen. Membranes were stripped and reprobed with a 32 P-labeled oligonucleotide probe speci®c for GAPDH to evaluate consistency of sample loading.
Plasmids and cloning
The putative promoters for human TrpRS were ampli®ed by PCR from HUVEC genomic DNA with the following oligonucleotides pairs: pES01 (forward, 5¢-cggaagatctCTTC-TAAAGCCAGCCAGCCAGC-3¢) and pES02 (reverse, 5¢-ggaattcTGCCCAGCCGGGCCAGTCAGCG-3¢) for ampli®-cation of putative promoter P1; pES03 (forward, 5¢-cggaagatctCACTGCACTGTGCCGCCTCGG-3¢) and pES04 (reverse, 5¢-ggaattcGGAAGACACTGCAGAGGTGGCC-3¢) for promoter P2; pES01 and pES04 for putative tandem promoters P1 + P2 (P12). The nucleotide sequences in lowercase and underlined BglII and EcoRI restriction sites were added for cloning PCR products between the BglII and EcoRI restriction sites of a luciferase reporter vector phRLnull (Promega) to give pP1-Luc, pP2-Luc and pP12-Luc, respectively. Mutant forms of g-activated sequence (GAS) or interferon-stimulated response element (ISRE) consensus sequences within the promoter constructs were created by site-directed mutagenesis with a QuickChange XL kit (Stratagene, La Jolla, CA) as follows: ISRE1 (±379 to ±369, 5¢-GTTTCCCTTTC-3¢®5¢-GTTTCCAGCGCC-3¢), ISRE2 (±55 to ±45, 5¢-GGAAACTGAAA-3¢®5¢-GAAAC-CTCGAG-3¢), ISRE3 (±1421 to ±1408, 5¢-CAAACACAA-AAC-3¢®5¢-CTTGCACAAAAC-3¢). Mutated nucleotides are underlined. Plasmids carrying human IRF-1 and IRF-2 in vector pcDNA (Invitrogen) were gifts from Drs Mark Perrella and Richard Riese at Brigham and Women's Hospital (Boston, MA). Endotoxin-free plasmid DNA was prepared with an EndoFree Plasmid Maxi Kit (Qiagen).
Transient transfection luciferase assays
Transient transfections of 60±70% con¯uent HUVEC or HeLa cells were performed with SuperFect transfection reagent (Qiagen) and each of the luciferase reporter vectors (5 or 10 mg) according to the manufacturer's instructions (Qiagen). After transfection, cells were incubated with fresh medium with or without IFN-g (100 U/ml) for 24 h. At the designated times, treated cells were rinsed with PBS and lysed for quanti®cation of luciferase. Luciferase activity was measured following the manufacture's protocol (Promega) using the Analyst AD Assay Development System (Molecular Devices, Sunnyvale, CA). Luciferase activity was initially calculated as relative luminescence units (RLU)/mg protein. Relative luciferase activity was expressed as (sample ± vector control)/vector control.
RESULTS
Multiple 5¢-untranslated regions (UTRs) of human TrpRS mRNA
Through extensive nucleotide BLAST searches of the human Expressed Sequence Tag (EST) database at the National Center for Biotechnology Information we deduced alternative splice variants of TrpRS from a variety of tissues/cell lines, including lung, prostate tumor, testis, brain, lymphoma, eye and skin. Unexpectedly, multiple 5¢-UTRs of TrpRS mRNA were identi®ed. Among the ®ve distinct sequences described here, two were novel and three were previously identi®ed (Fig. 1A) (23,25) . The two newly identi®ed variants showed excellent sequence identity downstream of exon II or exon III in TrpRS cDNA, but had unique sequences at their 5¢ ends.
Comparison of these nucleotide sequences to the genomic DNA sequence of human TrpRS showed that the 5¢-sequence of the two novel mRNAs corresponded to a previously unidenti®ed exon upstream of exon Ia. The existence of the upstream exon (exon ±Ia) strongly suggested that the ®ve different TrpRS mRNAs were generated by two different promoters and that transcription events initiated from exon ±Ia produced distinct TrpRS mRNAs due to alternative splicing (Fig. 1B) .
Analysis of human TrpRS promoters
Analysis of the 2000 bp DNA sequence upstream of the human TrpRS gene by the program MatInspector (35) revealed several potential interferon regulatory elements: two GAS at ±143 to ±134 (5¢-TTTCTGAGAA-3¢) and ±1553 to ±1545 (5¢-TTTCTGGAA-3¢); two ISRE at ±55 to ±45 (5¢-GGAAACTGAAA-3¢) and ±379 to ±369 (5¢-TTTCCC-TTTCC-3¢) (Fig. 1C). [The transcription response element positions are indicated relative to the transcription start site within exon Ia (as +1) (23) .] These response elements were located in two separate regions of the upstream 2000 bp of the TrpRS gene. One GAS element was located upstream of exon ±Ia between positions ±1545 and ±1553 within the region of the newly identi®ed promoter (named promoter P1 because it is in front of the previously identi®ed promoter P2). The other GAS element (23) and the two ISRE sequences (36) were located within the intervening sequence between exon ±Ia and exon Ia within promoter P2. This analysis suggested that both promoters (P1 and P2) would be responsive to IFN-g stimulation.
Regulation of TrpRS in HUVECs
Several human cell types up-regulate TrpRS and mini TrpRS expression in response to IFN-g (23,31±33). However, studies on TrpRS expression in HUVECs have not been previously reported. Because the proliferation and migration of HUVECs are inhibited by mini TrpRS, whether TrpRS expression was regulated by IFN-g in these cells was of obvious interest. The level of TrpRS mRNAs was measured by northern blot hybridization in HUVECs treated with IFN-g (50±500 U/ml IFN-g for 24 h). A dramatic increase in TrpRS mRNA was observed following IFN-g treatment ( Fig. 2A) , with maximum induction of~30-fold higher mRNA levels at 24 h than in HUVECs without IFN-g stimulation. The induction of TrpRS mRNA by IFN-g was also time-dependent, with a 10-fold increase in mRNA observed after 6 h IFN-g incubation (Fig. 2B) . The level of TrpRS mRNA continued to increase from 6 to 24 h, after which it reached a stable plateau after 48 h of treatment. The amount of TrpRS protein increased up to 10-fold after IFN-g stimulation (data not shown). Expression of another synthetase, TyrRS (which is not regulated by IFN-g), was not changed during this time. TrpRS expression was also examined in HUVECs following treatment with IFN-a, TNF-a, TGF-b, IL-4 and Epo, because earlier reports suggested that these factors modulated TrpRS expression in other cell types (32,37±39). However, none of these factors affected TrpRS expression in HUVECs, whether alone or in combination with IFN-g (data not shown). Collectively, these data demonstrate that human TrpRS expression in HUVECs was strongly and speci®cally stimulated by IFN-g in a doseand time-dependent fashion.
Alternative splice variants of TrpRS in HUVECs
Alternative splicing of TrpRS mRNA in HUVECs was examined by RT±PCR analysis. Two sets of oligonucleotide primers were used to PCR amplify cDNAs that corresponded to the various TrpRS mRNAs predicted from the EST analysis described above. The ®rst set of primers corresponded to exon Ia and exon III and the second set of primers corresponded to exon ±Ia and exon III (Fig. 3) . Ampli®cation with the ®rst set of primers gave three cDNA bands (isoforms 1±3) from HUVECs. The identities of the cDNA bands were determined by DNA sequencing and these three isoforms corresponded to those previously identi®ed from HeLa cells (23, 25) . To show the differences in TrpRS mRNA isoform production before and after IFN-g treatment, we used cDNA (prepared as described in Materials and Methods) that was diluted 1:100 in RT±PCRs. With this dilution, DNA bands representing different isoforms are barely visible before IFN-g treatment, while the level of all TrpRS mRNAs was increased following IFN-g stimulation (Fig. 3) . Ampli®cation with the second set of primers (±Ia and III) gave two cDNA bands (isoforms 4 and 5) in both HeLa cells (data not shown) and HUVECs (Fig. 3) . The amount of isoforms 4 and 5 increased following IFN-g stimulation (Fig. 3) . Among the ®ve TrpRS variants, isoforms 2 and 5 were relatively less than the other bands, which is consistent with the amounts of the corresponding protein products (data not shown) (24) . As an internal control, GAPDH mRNA was PCR ampli®ed from the same samples and the level was invariant.
Northern blot hybridization analyses were also carried out to evaluate the expression of different TrpRS mRNA isoforms. Four oligonucleotide probes were designed to hybridize to the distinct isoforms of TrpRS mRNA (Fig. 4) . Before IFN-g treatment, the mRNA level of each variant was low, while after IFN-g stimulation the amount of all variants increased in a dose-and time-dependent manner (Fig. 4) . Although it is dif®cult to determine the relative ratio between the TrpRS mRNA isoforms, it is clear that all the isoforms were strongly stimulated by IFN-g. These data were consistent with the results obtained from RT±PCR analysis. Together, these studies showed that two newly identi®ed TrpRS mRNA isoforms (4 and 5) were produced in HUVECs and HeLa cells in addition to the three previously reported forms (1, 2 and 3). The new isoforms have a unique 5¢ exon, but they share the characteristic IFN-g regulation of the previously known TrpRS isoforms. . RT±PCR analyses of IFN-g up-regulated TrpRS isoforms in HUVECs. Cells were treated with or without IFN-g (100 U/ml) for 24 h. Total RNAs were isolated and converted to cDNA. PCR was performed with cDNA (prepared as described in Materials and Methods and diluted 1:100) and analyzed by 1.2% agarose gel electrophoresis. Under these conditions, the differences between the levels of TrpRS mRNA isoforms could be seen. GAPDH is an internal control.
Two inducible promoters regulate TrpRS expression in HUVECs
We next sought to dissect the activity of the two TrpRS promoters using a promoter-driven luciferase assay. A series of luciferase reporter vectors was constructed containing different portions of the DNA region upstream of base +1 and extending 56 bp into exon Ia followed by the luciferase gene for direct readout of promoter activity (Fig. 5A) . Each construct was transiently transfected into HeLa cells and HUVECs and the relative luciferase activity was determined in the presence or absence of IFN-g. In HeLa cells, the basal level of luciferase expression from promoter P1, P2 or the combined promoter P12 was low. In contrast, IFN-g strongly stimulated luciferase expression from all three constructs, with the P2-Luc construct giving the most robust expression (Fig. 5B) . Similar results were obtained in HUVECs, where IFN-g treatment strongly induced luciferase expression (Fig. 5C ). This result was obtained from three independent experiments. Interestingly, in HUVECs, the basal expression of luciferase from promoter constructs P1-Luc, P2-Luc and P12-Luc was higher than that in HeLa cells. This result is consistent with the previous observation that TrpRS gene expression is higher in HUVECs compared to most other human tissues and cells (40) . We also noticed that the promoter activity of P12 is lower than that of promoter P2 alone in HUVECs, which is also observed in HeLa cells (23) . In summary, these data demonstrate that promoters P1 and P2 were functional promoters responsive to IFN-g stimulation.
IRF-1 activates TrpRS promoter activity
Because GAS sites are well de®ned and known to be activated by signal transducer and activator of transcription 1a subunit (STAT1), we focused on new features within the TrpRS promoter such as the potential ISRE motifs and their possible activator(s). Interferon regulatory factors (IRFs) belong to a growing family of transcription factors. Several recent reports showed that IRF-1, which itself is up-regulated by IFN-g, stimulates IFN-g-induced target gene expression by binding to ISRE consensus sites (41, 42) . IRF-2 is expressed constitutively and acts mostly as a repressor by competing with IRF-1 for the same binding site(s) (41, 43) . There were two potential ISRE consensus sequences identi®ed by the program MatInspector within promoter P2 that were potential binding sites for IRF-1. We examined whether overexpression of IRF-1 would activate TrpRS promoter activity independent of IFN-g stimulation. An IRF-1-containing expression vector was co-transfected into HeLa cells with each of the three promoter constructs. Overexpression of IRF-1 led to dramatic increases in P1, P2 and P12 promoter activity compared with cells transfected with empty vector in the absence or presence of IFN-g (Fig. 6 ). Endogenous TrpRS expression was also stimulated by IRF-1 overexpression in western blot analyses (data not shown). In contrast, co-transfection of IRF-2 had no effect on promoter activity. Because MatInspector did not identify a consensus sequence for ISRE in this promoter, it was surprising to ®nd that IRF-1 stimulated expression from promoter P1 (construct P1-Luc). However, upon closer inspection a nucleotide segment (±1421 to ±1408, 5¢-CAAACACAAAAC-3¢) was found that may serve as an ISRE and thus explain the effect of IRF-1 on P1-Luc.
To ®nd out which of the putative ISREs is involved in IRF-1 stimulation, we mutated each ISRE motif within promoters P1 and P2 (Fig. 7A) . Each construct was co-transfected with an IRF-1-containing vector into HeLa cells and the luciferase activity was measured. The putative ISRE motif within promoter P1 (ISRE3) was mutated, but the promoter activity was only marginally changed compared to that of wild-type P1 (Fig. 7B ). This result suggested that promoter P1 may contain an unidenti®ed nucleotide element to mediate IRF-1 stimulation or that the IRF-1 stimulation was regulated by a mechanism not requiring ISRE3. As shown in Figure 7C , mutation of ISRE1, associated with promoter P2, had a modest effect on luciferase activity, which decreased to~70% of wildtype P2. In contrast, when ISRE2 was mutated, the P2 promoter activity was strongly inhibited. When both ISREs were mutated (P2ab), there was no measurable luciferase activity. These results suggested that ISRE2 within promoter P2 was the primary site for IRF-1 binding and stimulation of TrpRS expression, while ISRE1 was needed for maximal expression.
DISCUSSION
TrpRS is overexpressed in guinea pigs during delayed-type hypersensitivity reactions (44) , in Drosophila during development of salivary gland (45) and in aged human epidermis (46) . Elevated TrpRS expression was also found in IFN-g-treated bladder transitional cells (47) . The increase in TrpRS levels during speci®c developmental events and in speci®c diseases may be a response related to its role in cell signaling. While the canonical function of human TrpRS is aminoacylation of tRNA Trp for protein synthesis, regulation of angiogenesis is an extended function provided by an alternative splicing variant (13, 14) . The regulation of expression of human TrpRS by IFN-g is perhaps related to this extended function. Supporting this idea, IFN-g was shown here to stimulate the production of the anti-angiogenic, N-terminally truncated variant.
Although previous data by others described TNF-a, TGF-b and Epo stimulation of TrpRS expression in certain cell types (38, 39) , in our studies those effects were not observed in HUVECs. None of these cytokines increased TrpRS expression whether alone or in combination. In contrast, TrpRS expression in HUVECs was speci®cally and robustly stimulated by IFN-g. Previous reports that IL-4 and TGF-b had a negative effect on IFN-g-induced TrpRS expression (37) led us to test these cytokines on HUVECs. However, neither IL-4 nor TGF-b had an effect on IFN-g-stimulated TrpRS expression. Thus, TrpRS expression in HUVECs was uniquely stimulated by IFN-g.
The new promoter (reported here) controlling expression was identi®ed within a 2000 bp region of the gene. [This promoter is upstream and in tandem with the previously identi®ed promoter (23) .] Overall, the 2000 bp region contains four IFN-g regulatory sequences and all elements needed to direct basal level TrpRS expression. Promoter P1 contains one GAS element, while promoter 2 contains one GAS element and two ISRE elements. Both promoters respond to IFN-g stimulation. The ®ve TrpRS mRNA variants seen in vivo [two new TrpRS mRNA isoforms identi®ed in this study and three isoforms reported previously (23, 25) ] result in expression of two protein forms, TrpRS and mini TrpRS. Expression of all ®ve TrpRS mRNA isoforms was stimulated by IFN-g (Figs 3  and 4) . That two promoters control the gene expression of TrpRS and mini TrpRS reveals that expression is complex and warrants further investigation.
Interferon signaling occurs by binding of IFN-g to a heterodimeric receptor that is linked to Janus kinases (JAKs) 1 and 2. Thus activated, JAK1/2 in turn activates STAT1, which is a transcription factor that translocates to the nucleus and activates several IFN-g-responsive genes through binding to GAS elements. Among the primary IFN-g response genes are some transcription factors, including IRF-1, which itself binds to ISRE elements to modulate gene expression (41, 42, 48) . The two TrpRS promoters examined here contained two GAS sites and two putative ISRE motifs. Previous work suggested that IFN-g stimulation of expression of human TrpRS involved STAT1 and the GAS site of promoter P2. However, IFN-g-sensitive expression of TrpRS could not be completely ascribed to the STAT1 transcription factor acting through the GAS site of the P2 promoter (23) . In this work, transcription factor IRF-1 and the new P1 promoter were demonstrated to be regulators in the IFN-g-sensitive expression of TrpRS, which thereby suggests a way to explain more broadly the IFN-g-related regulation of TrpRS expression. 
